Peer-Review Report of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (16784)
All Articles published online
|
Publishing Process of This Article
|
Sep 27, 2014 (publication date) through Mar 3, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Bonnet D, Guivarch M, Bérard E, Combis JM, Remy AJ, Glibert A, Payen JL, Metivier S, Barange K, Desmorat H, Palacin A, Nicot F, Abravanel F, Alric L. Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World J Hepatol 2014; 6(9): 660-669 [PMID: 25276282 DOI: 10.4254/wjh.v6.i9.660] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Bonnet D, Guivarch M, Bérard E, Combis JM, Remy AJ, Glibert A, Payen JL, Metivier S, Barange K, Desmorat H, Palacin A, Nicot F, Abravanel F, Alric L. Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World J Hepatol 2014; 6(9): 660-669 [PMID: 25276282 DOI: 10.4254/wjh.v6.i9.660] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v6/i9/660.htm |
| Number | Citing Articles |
| 1 |
Laurent Alric, Caroline Besson, Nathanael Lapidus, Juliette Jeannel, Jean-Marie Michot, Patrice Cacoub, Danielle Canioni, Stanislas Pol, Frédéric Davi, Pascaline Rabiega, Loic Ysebaert, Delphine Bonnet, Olivier Hermine, Ming-Lung Yu. Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. PLOS ONE 2016; 11(10): e0162965 doi: 10.1371/journal.pone.0162965
|
| 2 |
D. Salmon, F. Bani-Sadr, C. Gilbert, E. Rosenthal, M.A. Valantin, A. Simon, D. Neau, P. Morlat, M.A. Loko, L. Wittkop, F. Dabis. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. Journal of Clinical Virology 2015; 73: 32 doi: 10.1016/j.jcv.2015.10.010
|
| 3 |
João Paulo Vilela Rodrigues, Maurílio de Souza Cazarim, Silvana Gama Florencio Chachá, Ana de Lourdes Candolo Martinelli, Leonardo Régis Leira Pereira. Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. Cadernos de Saúde Pública 2020; 36(2) doi: 10.1590/0102-311x00036619
|
| 4 |
Alhambra Spanish Study Group, Rosa Quiles, Paloma Muñoz de Rueda, Ana Belén Martín, Miguel Fernández, Rafael Granados, José Luis Montero, Ramón Pérez, Francisco Javier Rodriguez, Francisco Jorquera, José Antonio Pons, Isabel Carmona, Dolores Espinosa, Conrado Fernández, Milagros Testillano, José María Navarro, Manuel Romero-Gómez, Moisés Diago, Ana Gila, Miguel Ángel Serra, Juan José Sánchez Ruano, Juan Manuel Pascasio, Rubén Berenguer, Carmen Vinaixa, Javier Salmerón. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World Journal of Gastroenterology 2015; 21(30): 9163-9174 doi: 10.3748/wjg.v21.i30.9163
|
| 5 |
Alessandra Mangia, Victor De Ledinghen, François Bailly, Javier Brahm, Jazeps Keiss, Jonas Valantinas, Nele Rasmann, Diethelm Messinger, Fernando Tatsch, Georgios Bakalos, Graham R. Foster. IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. SpringerPlus 2016; 5(1) doi: 10.1186/s40064-016-3663-6
|
| 6 |
Timothy A. Bach, Kathy Zaiken. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1–4 in an ambulatory care setting. American Journal of Health-System Pharmacy 2017; 74(5_Supplement_1): S1 doi: 10.2146/ajhp160567
|
| 7 |
Vanessa Costilla, Neha Mathur, Julio A. Gutierrez. Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment. Clinics in Liver Disease 2015; 19(4): 641 doi: 10.1016/j.cld.2015.06.005
|
| 8 |
J. Boursier, A. Ducancelle, J. Vergniol, P. Veillon, V. Moal, C. Dufour, J.‐P. Bronowicki, D. Larrey, C. Hézode, F. Zoulim, H. Fontaine, V. Canva, T. Poynard, S. Allam, V. De Lédinghen. The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients. Journal of Viral Hepatitis 2015; 22(12): 1002 doi: 10.1111/jvh.12433
|
| 9 |
Emma Gray, Suzanne Norris, Susanne Schmitz, Aisling O'Leary. Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. Journal of Comparative Effectiveness Research 2017; 6(1): 65 doi: 10.2217/cer-2016-0042
|
| 10 |
Antonia Lepida, Massimo Colombo, Inmaculada Fernandez, Djamal Abdurakhmanov, Paulo Abrao Ferreira, Simone I. Strasser, Petr Urbanek, Alessandra Mangia, José L. Calleja, Wafae Iraqi, Ralph DeMasi, Isabelle Lonjon-Domanec, Christophe Moreno, Heiner Wedemeyer, Vincent Wong. Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. PLOS ONE 2015; 10(9): e0138503 doi: 10.1371/journal.pone.0138503
|
| 11 |
Giulio De Stefano, Sebastiano Di Salvo, Raffaele Di Sarno, Nunzia Farella, Laura Felicioni, Basilio Fimiani, Luca Fontanella, Giuseppe Foti, Caterina Furlan, Francesca Giancotti, Giancarlo Giolitto, Tiziana Gravina, Barbara Guerrera, Roberto Gulminetti, Angelo Iacobellis, Michele Imparato, Angelo Iodice, Vincenzo Iovinella, Antonio Izzi, Alfonso Liberti, Pietro Leo, Gennaro Lettieri, Ileana Luppino, Aldo Marrone, Ettore Mazzoni, Vincenzo Messina, Roberto Monarca, Vincenzo Narciso, Lorenzo Nosotti, Adriano Maria Pellicelli, Alessandro Perrella, Guido Piai, Giorgio De Stefano, Rosanna De Marco, Antonio Di Giacomo, Giuseppe De Vita, Massimo De Siena, Vincenzo De Maria, Massimo De Luca, Pellegrino Dattolo, Emilio D’Amico, Giuseppe D’Adamo, Raffaele Cozzolongo, Ernesto Claar, Vincenzo Citro, Francesco Cesario, Michele Brogna, Giorgio Barbarini, Sergio Babudieri, Tiziana Ascione, Orlando Armignacco, Angelo Andriulli, Pietro Amoroso, Luigi Elio Adinolfi, Antonio Ascione, CLEO Study Group, Antonio Picardi, Paola Pierri, Grazia Pietromatera, Francesco Resta, Luca Rinaldi, Mario Romano, Angelo Rossini, Maurizio Russello, Grazia Russo, Rodolfo Sacco, Vincenzo Sangiovanni, Antonio Schiano, Antonio Sciambra, Gaetano Scifo, Filomena Simeone, Annarita Sullo, Pierluigi Tarquini, Paolo Tundo, Alfredo Vallone. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World Journal of Hepatology 2016; 8(22): 949-956 doi: 10.4254/wjh.v8.i22.949
|
| 12 |
Perica Davitkov, Apoorva Krishna Chandar, Amy Hirsch, Anita Compan, Marina G. Silveira, Donald D. Anthony, Suzanne Smith, Clare Gideon, Robert A. Bonomo, Yngve Falck-Ytter, Do Young Kim. Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C. PLOS ONE 2016; 11(10): e0163945 doi: 10.1371/journal.pone.0163945
|
| 13 |
Silvana Gama Florencio Chachá, João Paulo Vilela Rodrigues, Roberta Chaves Araújo, Leonardo Régis Leira Pereira, Márcia Guimarães Villanova, Fernanda Fernandes Souza, Rodrigo de Carvalho Santana, Ana de Lourdes Candolo Martinelli. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients. Revista da Sociedade Brasileira de Medicina Tropical 2018; 51(2): 146 doi: 10.1590/0037-8682-0153-2017
|